Urodynamix Presents First Data on Use of NIRS and Transurethral Microwave Therapy at the 26th World Congress of Endourology Conf

Urodynamix Technologies Ltd. (TSX VENTURE:URO) announced today that a
multinational team will present an abstract highlighting the use of Urodynamix's
near infrared spectroscopy (NIRS) technology for non-invasive measurement of
blood flow changes during minimally invasive treatments for benign prostatic
hyperplasia (BPH).


The abstract, entitled "Initial report of near infrared spectroscopy (NIRS) for
non-invasive measurement of blood volume and flow changes to provide treatment
feedback during prostate thermal therapies for BPH" will be presented by Prof.
Limin Liao of the China Rehabilitation Research Center, David Robertson of
Boston Scientific Corporation, and Dr. Luya Li of Urodynamix Technologies. The
published abstract will be posted to Urodynamix's website and will also appear
on the World Congress of Endourology website at www.chinamed.com.cn/wce2008. The
presentation will take place at the 26th Annual Meeting of the World Congress of
Endourology (WCE) at the Shanghai International Convention Center, November 30,
2008 in Shanghai, China.


A current limitation of transurethral microwave thermotherapy (TUMT) devices is
that individual variations in prostate blood flow can limit the effectiveness of
the procedure by removing the energy directed at the prostate during the
treatment. Urodynamix is developing a non-invasive prostate blood volume flow
monitor to help physicians determine when sufficient thermal energy has been
delivered by TUMT and other minimally invasive therapies to destroy enlarged
prostate tissue and BPH while improving the safety profile.


About the Study

Animal studies were conducted by Prof. Limin Liao at the Capital Medical
University in Beijing from June 2007 to November 2008. The investigators
collected NIRS readings simultaneously with the delivery of TUMT with the
Prolieve(TM) Thermodilatation System manufactured by Boston Scientific Corp. The
results showed that NIRS monitoring of the prostate and rectal wall for changes
in blood volume-flow may provide the ability to non-invasively monitor the
progress of tissue coagulation and necrosis during thermal therapies. This may
allow physicians to optimize treatment despite variations in prostate blood flow
of individuals.


About the World Congress of Endourology

The 26th World Congress of Endourology (WCE) conference is being organized by
the Chinese Urological Association (CUA) in association with Chinese Medical
Association, under the auspices of the Endourological Society.


About Urodynamix Technologies Ltd.

Urodynamix Technologies is a Canadian medical device company developing and
commercializing non-invasive medical technology based on proprietary
applications of near-infrared spectroscopy (NIRS). The Company is currently
focused on products that aid in the diagnosis and treatment of urinary
incontinence, lower urinary tract symptoms, prostate cancer, erectile
dysfunction, benign prostatic hyperplasia, and traumatic increases in
intra-abdominal pressure that cause abdominal compartment syndrome. Urodynamix's
breakthrough medical technology has the potential to beneficially affect more
than 200 million people worldwide.


Certain information contained in this press release may be forward-looking and
is subject to unknown risks, which could cause actual results to differ
materially from those set forth or implied herein. Although the Company believes
that the expectations reflected in such forward-looking statements are
reasonable, it can give no assurance that such expectations will prove correct.

Urodynamix Technologies Ltd. (TSXV:URO)
Graphique Historique de l'Action
De Juil 2024 à Août 2024